Method for the isolation of antibodies with functional activity against cell surface targets

“针对细胞表面靶标具有功能活性的抗体的分离方法” 摘要 我们开发了一种针对细胞表面受体分离功能性单克隆抗体的方法，这些受体分别是 激动剂、拮抗剂和部分激动剂。我们将这种方法称为定向配体结合（DLB）。 在 DLB 的第一次迭代 (DLB1) 中，我们已成功将其用于肽和蛋白质配体。使用 DLB1这些配体通过基因整合到互补决定区（CDR）中 合适的噬菌体展示 scFv 文库。从本质上讲，DLB 是一种引导或偏置初始绑定的方法 扣除（以去除非特异性和不相关的结合）噬菌体向靶标展示的抗体库的 通过将该受体的配体或抑制剂整合到抗体库本身中来确定细胞表面受体结合位点。 然后依靠单个 mAb 的 CDR 和 共价连接的配体可暂时稳定 Ab:: 受体复合物以承受不断增加的 用于去除任何弱结合物的噬菌体生物淘选洗涤循环的严格性。在DLB1 方法中，我们将配体基因编码到抗体的 CDR 中。但这将我们限制在肽和蛋白质上 配体。我们现在想要应用 DLB 方法将配体酶促缀合成 适当修饰的互补文库的CDR。我们将这种新方法称为DLB2.0。的 DLB2.0方法的显着优点有几个，包括：（1）可以使用相同的库 对于许多屏幕，以及 (2) 测试源自 DLB2.0 的单克隆抗体的方法（带或不带附件） 配体是微不足道的；只需省略任何屏幕之前的配体附着步骤即可。拟议的研究使用了几种 GPCR 靶点作为模型，功能在基于细胞的报告基因检测中作为应用。关于 商业应用，我们主要关注的是方法。确实，我们的目标 选择开发的方法在某些情况下并不具有特殊的商业价值。当 DLB2.0 生成适当的 IgG，我们打算与强大的学术界合作，并且 制药和生物技术公司为他们提供 IgG 克隆和/或纯化的 IgG 蛋白 以便他们能够进行更好地理解和利用所需的结构和生物学研究 我们开发的单克隆抗体。 Abbratech 打算为商业实体提供定制服务 （制药和生物技术公司）使用从本工作中获得的数据，包括任何 协作成果，作为DLB2.0力量的展示。

“Method for the isolation of antibodies with functional activity against cell surface targets” ABSTRACT We have derived a method for isolating functional mAbs against cell surface receptors that are separately either agonists, antagonists, and partial agonists. We termed the method Directed Ligand Binding (DLB). And in DLB’s first iteration (DLB1) we have successfully used it for peptide- and protein ligands. Using DLB1 these ligands were genetically incorporated into the complementarity determining region (CDR) of an appropriate phage display scFv library. At its essence DLB is a means to direct or bias the initial binding of a subtracted (to remove non-specific- and irrelevant binding) phage displayed Ab library toward a target cell surface receptor binding site by incorporating that receptor’s ligand or inhibitor into the Ab library itself. And then rely on the increased binding ability, via the interaction of both an individual mAb’s CDRs plus the covalently attached ligand to transiently stabilize the Ab::receptor complex to withstand the increasing stringency of the phage biopanning washing cycles used to remove any weak binders. In the DLB1 method, we genetically encoded the ligand into the Ab’s CDR. But that limited us to peptide and protein ligands. We now want to apply the DLB method for the enzymatic conjugation of ligands into an appropriately modified CDR of a complementing library. We refer to this new method as DLB2.0. The significant advantages of the DLB2.0 method are several fold, including: (1) the same library can be used for many screens, and (2) the means for testing mAbs derived from DLB2.0 with and without attached ligand is trivial; just omit the ligand attachment step before any screen. The proposed study uses several GPCR targets as the model and functionality in a cell-based reporter assay as the application. Regarding the commercial application, we are mainly focused on the method. It is true that the targets we have chosen to develop the method, in some cases, do not have exceptional commercial value. When the DLB2.0 generates appropriate IgGs we intend to partner and collaborate with strong academic, and pharmaceutical- and biotech companies by providing them with the IgG clones and/or purified IgG proteins so that they can perform the structural and biological studies needed to both better understand and utilize the mAbs we develop. At Abbratech intend to provide custom services to commercial entities (Pharmaceutical and Biotechnology companies) using the data obtained from this work, including any collaborative results, as a demonstration of the power of DLB2.0.